← Human Trials & Peer-Reviewed Studies
Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
Plain-language guide to PMID 27639082 (2016): double-blind randomized controlled trial study of Exenatide, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 27639082
- Journal
- Hepatology (Baltimore, Md.)
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Gastaldelli A et al. (11 authors)
- DOI
- 10.1002/hep.28827
- Registered trial
- NCT01588418
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Exenatide in the context of insulin resistance, prediabetes & type 2 diabetes.
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1-RAs) act on multiple tissues, in addition to the pancreas.
Thus, the researchers evaluated the acute effects of exenatide (EX) on hepatic (Hep-IR) and adipose (Adipo-IR) insulin resistance and glucose uptake.
Who Took Part
The age groups tagged for this paper are middle-aged adults, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.
As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.
What Was Measured
Thus, the researchers evaluated the acute effects of exenatide (EX) on hepatic (Hep-IR) and adipose (Adipo-IR) insulin resistance and glucose uptake.
During OGTT, the researchers measured hepatic (HGU) and adipose tissue (ATGU) glucose uptake with [18 F]2-fluoro-2-deoxy-D-glucose/positron emission tomography, lipolysis (RaGly) with [U-2 H5 ]-glycerol, oral glucose absorption (RaO) with [U-13 C6 ]-glucose, and hepatic glucose production (EGP) with [6,6-2 H2 ]-glucose.
PubMed files the paper under topics including Adipose Tissue, Exenatide, Glucose, Hypoglycemic Agents, Insulin Resistance, Liver and Peptides.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide in people with insulin resistance, prediabetes & type 2 diabetes.
Results are reported in around 1 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2016 (Hepatology (Baltimore, Md.)), a journal based in United States.
More context: the Exenatide compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.